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Abstract 
 
The QClamp® BRAF Codon Specific Mutation Detection Kit is a real-time PCR 
assay for the detection of somatic mutations in codon 600 Valine at exon 15 in 
the BRAF gene which encodes the serine/threonine protein kinase, using purified 
DNA. The V600E mutation is the most common BRAF gene mutation found in 
human cancers.  This mutation leads to production of a BRAF protein that is 
abnormally active, which disrupts regulation of cell growth and division. 
Mutations in this gene have been found in cancers, including non-Hodgkin 
lymphoma, colorectal cancer, malignant melanoma, papillary thyroid carcinoma, 
non-small-cell lung carcinoma, gastric cancer, and even prostate cancer.  
Currently, the established qPCR protocol for the QClamp® BRAF Mutation 
Detection Assay is comprised of a 4-step procedure:  Denaturation, XNA 
Annealing, Primer Annealing and Extension.  The purpose of this experiment was 
to test the feasibility of optimizing this assay to a more efficient and faster 2-step 
Real-time PCR which has just the Denaturation and the Primer 
Annealing/Extension steps.  Optimization was attempted on both the ABI-QS5 
and LC480 thermocycling instruments using parallel testing.  The newly 
established 2-step thermocycling parameters were successfully tested and 
validated on the ABI-QS5 instrument.  For the LC480, however, the experiment 
was not successful.  This result might be due to the different platforms and 
technologies of the two instruments.  Further research is needed to develop the 
mutational status scoring and acceptance criteria for clinical samples on the ABI-
QS5, and to complete the development of the 2-step qPCR protocol individually 
on the LC480, and also, to study the effects of factors such as temperature, ramp 
rates, PCR enzymes/master mix, primer/probes and XNA concentrations for both 
ABI-QS5, and the LC480. 
 
KEYWORDS:  2-step PCR, 2-step Real-time PCR, 2-step qPCR protocol, 
combined annealing/extension protocol, XNA oligomers, BRAF c600 
mutation, The QClamp® BRAF Codon Specific Mutation Detection Kit.
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Introduction 
 
BRAF is a human gene that encodes a protein called B-Raf formally known 
as serine/threonine-protein kinase B-Raf. This protein is part of a signaling 
pathway known as the RAS/MAPK pathway which helps transmit chemical 
signals from outside the cell to the cell's nucleus and regulates cell growth and 
proliferation.  The BRAF protein is also known as 94 kDa B-raf protein; p94; B-raf 
1; BRAF1; BRAF1_HUMAN; B-Raf proto-oncogene serine/threonine-protein 
kinase.  The gene, also known as murine sarcoma viral (v-raf) oncogene 
homolog B1; RAFB1; and v-raf murine sarcoma viral oncogene homolog B, 
belongs to a class of genes known as oncogenes which have the potential to 
cause normal cells to become cancerous when mutated.  The chromosomal 
location/cytogenetic location is: 7q34, which is the long (q) arm of chromosome 7 
at position 34.  The molecular location is: base pairs 140,719,331 to 140,924,764 
on chromosome 7 (Genetics Home Reference):   
 
Figure 1:  Location of BRAF gene 
BRAF V600 is a specific location in the BRAF gene which causes a change in 
the B-RAF protein.  This mutation causes the BRAF protein to be abnormally
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active, which disrupts regulation of cell growth and division; therefore, leads to 
the increase in growth and spread of cancer cells.  The V600E mutation is the 
most common BRAF gene mutation.  Approximately 80–90% of BRAF V600 
mutations are V600E, which is the result of a single amino acid substitution from 
valine (V) to a glutamic acid (E) at codon 600 in BRAF gene (My Cancer 
Genome).  This specific mutation along with several other somatic mutations in 
the BRAF gene are found in different types of human cancers including non-
Hodgkin lymphoma, colorectal cancer, malignant melanoma, papillary thyroid 
carcinoma, non-small- cell lung carcinoma, gastric cancer, and even prostate 
cancer.  Targeting BRAF mutations in tumor tissue using real-time PCR aides in 
the cancer detection and treatment (Cancer Genetics Web). 
 
Background 
 
QClamp® Technology for Mutation Detection -  
 
The QClamp® BRAF Codon 600 Specific Mutation Detection Kit is a real-time 
PCR assay for the detection of somatic mutations in codon 600 (Valine) at exon 
15 of the BRAF gene using purified DNA.  This kit identifies the presence or 
absence of mutations in the targeted region using the The QClamp® or the 
xenonucleic acid (XNA) mediated PCR clamping technology but does not specify 
the exact nature of the mutation.  XNA is a synthetic DNA analog with 
phosphodiester backbone replaced by a novel synthetic backbone chemistry 
(DiaCarta’s proprietary novel uncharged backbone chemistry).  XNAs are
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designed to hybridize tightly to complementary DNA target sequences with a 
complete match to wild-type DNA only.  XNA oligomers are not recognized by 
DNA polymerases and cannot be utilized as primers in subsequent real-time 
PCR reactions.  Therefore, specific-target binding of XNA blocks strand 
elongation by DNA polymerase so when there is a mutation in the target site, 
hence a mismatch in the sequence, the XNA:DNA binding is unstable causing 
the XNA probes to fall off allowing amplicon extension by DNA polymerase.  
Thus, addition of an XNA to a PCR reaction, blocks amplification of wild-type 
DNA allowing selective amplification of mutant DNA (DiaCarta Inc., QClamp® 
BRAF Codon Specific Mutation Test in Codon 600 Instruction Manual – 
Research Use Only).  See illustration below: 
 
 
       
Figure 2: Principle of The QClamp® Technology.  The detection kits are designed to detect any                                 
mutation at or near the stated codon site without specifying the exact nucleotide change. 
 
(From the QClamp® BRAF Codon Specific Mutation Test in Codon 600 - Instruction Manual 
(RUO) MAN.0006 Rev.
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Purpose 
 
The QClamp® BRAF Codon Specific Mutation Test in Codon 600 Real-time PCR 
(qPCR) assay was developed and validated on several of the ABI instruments 
and the Roche Light-Cycler platforms using traditional cycling steps:   
Denaturation, XNA Annealing, Primer Annealing and Extension.  In this 
experiment, the focus was to maximize throughput and to optimize this assay to 
a faster PCR test by using the 2-Step Real-time PCR (qPCR) protocol with just 
Denaturation, and Annealing/Extension parameters. 
 
Materials 
 
The BRAF Codon Specific Mutation Test in Codon 600 Kit reagents were used in 
this experiment.  The assay detects specific changes in Codon 600 as depicted 
in the Table-1: 
 
 
 
 
 
 
 
 
 
 
    
 
 
The following tables list all the materials (samples, controls, reagents) in the kit, 
and the instruments used in the experiment:          
Exon Amino Acid Change Nucleotide change 
 
 
15 
V600>E c1799T>A 
V600>K c1798_1799GT>AA 
V600>D c1799_1800TG>AT 
V600>R c1798_1799GT>AG 
V600>M c1798G>A 
Table 1:  Listed specific mutational changes in Codon 600 at Exon 15 of 
BRAF Gene.  QClamp® BRAF Codon Specific Mutation Test. 
Kit identifies specific changes in Codon 600 at Exon 15. 
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For the purpose of this experiment, all samples including the College of American 
Pathologist (CAP) proficiency test samples were purified genomic DNA, so the 
extraction step was not necessary.  The BRAF c600 Mutant Templates, which is
Company Instrument Model 
Roche  Light cycler 96 
Roche  Light cycler 480 II 
ABI  QS5 
Assay Components Volume/Reaction 
2X PCR Master mix  5 μl 
Primer and probe Mix  2 μl 
V600 XNA  1 μl 
DNA sample or Controls  2 μl 
Total volume  10 μl 
Table 3:  Samples and Reagents used per 10μl total 
assay volume with 5ng DNA input, and as low as 
0.5% mutant allelic frequency. 
 
Table 2:  LC96 was used for the Temperature Gradient       
Analysis.  Optimization was performed on both the 
LC480 and the ABI-QS5. 
Reagents Description Starting 
Conc. 
Vol. 
in a 
10ul 
assay 
Final 
Conc. 
Test 
Samples 
Description Starting 
Conc. 
Vol. in 
a 10ul 
assay 
Final 
Conc. 
2X PCR 
Master Mix 
PCR Master Mix 2x 5ul 1x DNA 
template 
Undiluted Positive 
template 
2.5ng/ul 
of DNA 
2ul 5ng of 
DNA input 
5X BRAF 
c600 Primer/ 
Probe Mix 
BRAF V600 
Primers and 
Probes 
5x 2ul 1x DNA 
template 
0.5 % mutant allele 
frequency Positive 
template 
2.5ng/ul 
of DNA 
2ul 5ng DNA 
input 
10X BRAF 
c600 XNA 
BRAF V600 XNA 10x 1ul 1x CAP 
samples 
 
Undiluted 
 
2.5ng/ul 
of DNA 
2ul 5ng of 
DNA input 
 
Controls 
 
Description 
 
Starting Conc. 
 
Vol. in a 10ul 
assay 
 
Final 
Conc. 
 Negative Control 
 (Clamping Control – CC) 
Wild-Type DNA Templates 2.5ng/ul 
of DNA 
 
2ul 
5ng of 
DNA input 
Mixed 
Positive Control (PC) 
BRAF c600 Mutant Templates 2.5ng/ul 
of DNA 
 
2ul 
5ng of 
DNA input 
Non-template control (NTC) Nuclease-Free Water -  
2ul 
- 
Table 4:  Details of specific volume and concentration of reagents and samples used in experiment. 
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the Positive Control (PC) of the assay kit, is pre-made with a 5% mutant allele 
frequency.  The final DNA concentration for each sample used in this experiment 
was of 5ng DNA input.  For the Limit of Detection (LOD) study, a positive sample 
was prepared with mutant allelic frequency of 0.5%.  This was done by diluting 
the 5% mutant DNA Positive Control (PC) into the Wild-Type (WT) DNA 
Templates.  WT-DNA Templates, also known as the Negative Control or 
Clamping Control (CC), PCR Master Mix, 5X BRAF c600 Primer/Probe and the 
10X BRAF c600 XNA were all obtained directly from the assay kit.
Methods 
 
The current 4-Step with Melt Curve protocol is set as listed in Table – 5 for each 
assay run on the ABI instruments.  Meanwhile, Table – 6 lists the thermocycling 
parameters set for the Light-Cycler platforms with specific ramp rates: 
 
 
 
 
 
Steps Temperature (°C) Time (Seconds) Cycles 
Preincubation  95 300 1 
Denaturation  95 20  
 
X50 
 
XNA Annealing  70 40 
Primer Annealing  66 30 
Extension  72 30 
Melt Curve Default - - 
Table 5:  Current Applied Biosystems Platforms Thermocycling Protocol. 
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To optimize this assay by reducing the run time for a faster real-time PCR test, a 
2-step qPCR protocol (combining annealing and extension into one step) was 
considered.  In general, when using primers with annealing temperatures 
between 70-72°C such as the ones seen here for XNA, a 2-step thermocycling 
protocol is possible.  Since most polymerases are highly active at the typical 
primer annealing temperature range of 55-70oC (Bio-Rad), a single run of the 
Temperature Gradient Analysis would show the optimal annealing temperature 
that can be used for this combined protocol.  The followings were steps taken to 
design and validate this 2-step qPCR assay: 
Optimization and Validation Steps 
 
1).  Temperature Gradient Analysis performed to find the optimum 
annealing/extension temperature for the assay: 
 
For the BRAF V600 – Gradient Analysis, using the LC96 instrument and the 
white 96-well PCR plate, a set of samples: one Negative or Clamping Control 
(CC), and one Positive Control (PC) - BRAF V600 Mutant DNA Templates, were 
plated from column 1-11 along with a set of two Non-Template Controls (NTC) - 
Steps Temp (°C) Time (Sec) Cycles Ramp Rate 
 
Preincubation  95 300 1 4.4 
Denaturation  95 20  
 
 
X50 
2.2 
XNA Annealing  70 40 2.2 
Primer Annealing  64 30 2.2 
Extension  72 30 1.0 
Melting  95 10 4.4 
 
Melting  
Cooling  
65 60  
1 
1 
2.2 
97 1 0.2 
37 30 2.2 
Table 6:  Current Thermocycling Protocol for the LC96 and LC480 Platforms. 
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Nuclease-Free Water, plated at the end at column 12 were run.  The temperature 
gradient range was set from 61oC to 68oC/30sec.   
2).  Optimization Experiments performed on both the ABI QS5 and LC480 
instruments by running parallel tests: 
 
From the results obtained in the Temperature Gradient Analysis, the optimal 
temperature selected was 63oC.  The previous 4-step PCR protocol was reduced 
to a 2-step qPCR protocol as listed in the following Table – 7: 
 
 
 
 
 
Optimization of PCR was attempted for both the ABI-QS5 and LC480 cyclers 
simultaneously with same set of CC, PC and NTC samples, all tested in 
triplicates.  
3).  Evaluation of Reproducibility, and Assay Precision:  
 
To assess the Intra-Assay Precision, replicate results of the same sample in  
the Limit of Detection Study were calculated for within-run reproducibility.   Inter- 
Assay Precision for between-runs study was done by observing the replicate
Steps Temperature (°C) Time 
(Seconds) 
Cycles 
Preincubation  95 300 1 
Denaturation       (1) 95 30  
X50 
 
XNA Annealing  
Primer Annealing  
Extension            (2) 
 
63 
 
 
40 
Melt Curve Default - - 
Table 7:  Newly established 2-Step qPCR Protocol for the ABI-QS5. 
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results of the same set of PC, and CC samples tested in separate runs, and on 
different days using the same instrument, the ABI-QS5.  Data were calculated; 
standard deviation (SD) and coefficient of variation (%CV) values were produced 
to evaluate assay reproducibility/precision. 
4).  Limit of Detection (LOD) Test:  
 
Reference Mutant DNA Templates was diluted with the WT DNA Templates (CC) 
to obtain a Positive Mutant DNA sample of 0.5% mutant allelic frequency at 5ng 
DNA input.  This diluted sample was then run along with a Clamping Control 
(CC), repeatedly 10 times each for the study of LOD.   
5).  Accuracy study using CAP samples:  
 
To evaluate the accuracy of our method on the ABI-QS5, a panel of 4 previously 
tested CAP proficiency testing samples with known results were tested along 
with the Negative Clamping (CC) and Positive Control (PC), all in duplicates plus 
1 Non-Template Control (NTC) using the newly established 2-step qPCR 
protocol.  Results were observed and compared with known values. 
 
Results 
 
In this experiment, the assay generates a cycle threshold (Ct) value for each 
sample at both the FAM and HEX (the 2 dyes used by the thermal cyclers) 
channels.  FAM dye is used to detect the BRAF amplification of WT and Mutant 
10 
 
DNA whereas the HEX dye is used to detect the Beta Actin gene amplification, 
which acts as the Internal Control (IC). When assessed using the HEX channel, 
internal control should make amplicons efficiently for all samples and controls 
except NTC, providing a way to monitor performance of the primers, probes, 
polymerase, and sample DNA quality/quantity.  Ct is the cycle number at which a 
signal is detected above the set threshold for fluorescence. The lower the Ct, the 
stronger the PCR reaction it represents.  Since this is a newly developed 2-step 
qPCR protocol using the QClamp® BRAF Codon 600 Specific Mutation 
Detection Kit, no set criteria have been established for result interpretation, 
therefore, the following guidelines were set for the validity of the experiment.  
These acceptance criteria were derived from previous in-house experiments and 
studies with this kit and similar assays using the same testing platforms.  
Data Analysis   
 
Acceptance Guidelines: 
  
The Ct of the Clamping Control (CC) with each of the mutation reaction mixes 
should be at least 5 Ct greater than the Ct of the Positive Control (PC) with the 
same reaction mix, observed in the FAM channel: 
CCCt – PCCt must be >5.00 
This ΔCt value of >5.00 was chosen so that enough variation gap is allowed to 
distinguish between Negative and Positive samples.  In addition, the validity of 
the assay is assured with the use of the Ct value from the Internal Control (IC) 
mix.  The Ct values for the Internal Control (observed in the HEX channel) should
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be in the range of 25< Ct <31 for all samples:   
ICCt should be = 25 < Ct < 31 
If these criteria are not met, the PCR assay did not work, and the results are 
invalid.    
Experimental Results   
The Temperature Gradient Analysis was successful with a single run on the 
LC96, and the optimal annealing-extension temperature was established at 63oC 
based on the highest ΔCt (threshold cycle) value calculated from the BRAF V600 
WT, and the BRAF V600 PC results at column 4 (position A4 and B4).  Hence 
the optimal temperature obtained was of the highest ΔCt value 6.37 (Figure – 3 
and Table – 8).  
 
Figure 3:  Temperature Gradient Analysis performed on the LC96.  Same samples:  1 Positive and 1 Negative Control 
run repeatedly from column 1 to 11 with temperature range set at 61oC –68oC.  Non-Template Control run at column 
12).  Column 4 at 62.8oC is where highest ΔCt value was detected. 
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Table - 8:  TEMPERATURE GRADIENT ANALYSIS DATA - BRAF V600 WT or the Clamping Control (CC) along with 
Mutant DNA templates (PC) were used.  Optimal annealing/extension temperature were obtained from calculating the 
ΔCt value at each column and selecting the highest value: (A4) CCCt – (B4) PCCt = 37.28 – 30.91= 6.37. The internal 
control (IC) Ct values shown in the Hex channel are = 25 < Ct < 31 which also serve as a reference for the assay validity 
for the detection of mutations. 
 
The optimization experiment was carried out on both the ABI-QS5 and LC480 at 
first using the 63oC/30sec for annealing and extension parameter.  Test results 
were acceptable but not optimal for the ABI-QS5 (ΔCt values were around 5), 
and there was no DNA amplification observed at all on the LC480.                 
Since previously tested and validated data obtained in-house shown that usually, 
the LC480 runs optimally at 2oC lower than the ABI-QS5, the annealing/extension 
temperature was modified to 61oC for the LC480 on subsequent runs, and the
Position Sample Name Ct Dye Position Sample Name Ct Dye 
A1 BRAF V600 WT 36.6 FAM B1 BRAF V600 PC 31.4 FAM 
A1 BRAF V600 WT 25.2 Hex B1 BRAF V600 PC 26.17 Hex 
A2 BRAF V600 WT 35.71 FAM B2 BRAF V600 PC 30.22 FAM 
A2 BRAF V600 WT 25.27 Hex B2 BRAF V600 PC 26.06 Hex 
A3 BRAF V600 WT 36.11 FAM B3 BRAF V600 PC 31.14 FAM 
A3 BRAF V600 WT 25.4 Hex B3 BRAF V600 PC 26.18 Hex 
A4 BRAF V600 WT 37.28 FAM B4 BRAF V600 PC 30.91 FAM 
A4 BRAF V600 WT 25.44 Hex B4 BRAF V600 PC 25.97 Hex 
A5 BRAF V600 WT 35.66 FAM B5 BRAF V600 PC 29.31 FAM 
A5 BRAF V600 WT 25.63 Hex B5 BRAF V600 PC 25.78 Hex 
A6 BRAF V600 WT 35.38 FAM B6 BRAF V600 PC 30.64 FAM 
A6 BRAF V600 WT 25.55 Hex B6 BRAF V600 PC 25.99 Hex 
A7 BRAF V600 WT 35.19 FAM B7 BRAF V600 PC 30.76 FAM 
A7 BRAF V600 WT 25.84 Hex B7 BRAF V600 PC 26.16 Hex 
A8 BRAF V600 WT 37.69 FAM B8 BRAF V600 PC 31.13 FAM 
A8 BRAF V600 WT 26.21 Hex B8 BRAF V600 PC 26.25 Hex 
A9 BRAF V600 WT 39.81 FAM B9 BRAF V600 PC 30.96 FAM 
A9 BRAF V600 WT 26.69 Hex B9 BRAF V600 PC 26.68 Hex 
A10 BRAF V600 WT - FAM B10 BRAF V600 PC 32.07 FAM 
A10 BRAF V600 WT 27.2 Hex B10 BRAF V600 PC 27.16 Hex 
A11 BRAF V600 WT - FAM B11 BRAF V600 PC 38.41 FAM 
A11 BRAF V600 WT 28.5 Hex B11 BRAF V600 PC 28.43 Hex 
A12 Sample 12 - FAM B12 Sample 24 - FAM 
A12 Sample 12 - Hex B12 Sample 24 - Hex 
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annealing-extension time was extended to 40 seconds as well.  ABI-QS5 was still 
set at 63oC but with 40 sec annealing-extension time also to optimize assay 
performance.  Different ramp rates and concentrations of BRAF 600 XNA (0.8x 
and 1.3x) beside the original 1x were also tested in the optimization study.  The 
results showed both the 0.8 and the original 1x concentrations for XNA primers 
worked comparably well with the new 2-step qPCR protocol on the ABI-QS5 
cycler.  However, reactions with 1.3x concentration of XNA did not amplify.  The 
revised protocol of 61oC/40sec on the LC480 also resulted in poor amplification 
even with different ramp rates selected.  More time and further research are 
needed to individually study and optimize the diagnostic performance of the 2-
step qPCR protocol on the LC480.  The optimization experiment for this thermal 
cycler was, therefore, unsuccessful.  The plan for this experiment was to perform 
the optimization assay on both the ABI-QS5 and the LC480 simultaneously for 
Comparison Study.  However, optimization on the LC480 could not be completed 
with the newly established 2-step qPCR protocol.  As a result, validation 
proceeded on the ABI-QS5 only and the results were as followed: 
1.  Precision:    
  
The acceptance criteria for precision was that ΔCt values obtained satisfied the 
cut-off value for distinguishing positive from negative mutations, and the range of 
ΔCt results is acceptable and within ± 2SD (standard deviation) of the mean.  
Although the %CV is slightly high due to the small set of data, the tested range of 
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ΔCt values is well within the 95% of Normal Distribution curve as seen in Fig-2 
below:   
                                   
   
  ΔCt values 
 
 
                                                                          
 
 
Table 9:  List of Precision Study Data.  Data and the 
following formulas were used to calculate Between-Runs 
Total Mean of ΔCt, Total Standard Deviation (SD), and 
the Coefficient of Variation (CV) for the Precision Study: 
 
 
 
 
 
2.  Limit of Detection (LOD): 
  
For the evaluation of LOD, reference DNA samples of 0.5% mutant allelic 
frequency with 5ng DNA input was utilized and run a total of 10 times along with 
the Clamping Control (CC).  All 10 replicates of the diluted reference Mutant DNA 
PRECISION 
STUDY 
Within-
Run 
Between-Runs 
 
Replicates 
  
(ΔCt) 
Run #1  
(ΔCt) 
Run #2 
(ΔCt) 
Run #3  
(ΔCt) 
1 6.42 6.46 12.05 8.36 
2 6.43 9.16 10.88 7.97 
3 6.40 9.15 11.74 - 
4 5.41 - 12.90 - 
5 7.47 - 11.34 - 
6 5.01 - 9.36 - 
7 6.80 - - - 
8 6.54 - - - 
9 6.48 - - - 
10 7.10 - - - 
Test Count: 10 3 6 2 
Average: 6.41 8.26 11.38 8.17 
SD: 0.73 1.56 1.20 0.28 
 
Total Average = 
9.27 
Total SD =  
1.83 
%CV = CV x 100 
19.72 
+2SD 
-2SD 
Figure 4: Normal Distribution Curve of ΔCt values 
between ±2SD.  Area (probability) = 0.9545. 
Figure 5:  Plot of ΔCt precision data.  X-axis 
= Sample Replicates, Y-axis = ΔCt values 
(from Table-9).  Horizontal central line 
indicates the mean of the ΔCt values.  
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sample were tested positive using the 2-Step qPCR protocol on the ABI-QS5. 
Therefore, 0.5% mutation frequency can be readily detected at 5 ng DNA input.  
Further studies will be needed to test if the assay can detect mutations at lower 
allelic frequencies than 0.5%.  
3.  Accuracy: 
  
Four CAP specimens, Sample 1: 15A002, Sample 2: 16A054, Sample 3: 16A055 
and Sample 4: 16A056 were run in duplicates each, along with a CC, a PC and 1 
NTC control samples for accuracy study and clinical evaluation.  All IC Ct values 
in the Hex channel = 25 < Ct < 31, which met the acceptance criteria and 
validated the assay.  CAP results were in concordance with the expected values:  
S1 and S4 were negative, and S2 and S3 tested positive for BRAF c600 mutant 
gene.  
Based on the “Gaussian Distribution” model and the formula:  Mean ± (1.96 x 
SD), and with the calculated total SD and the ΔCt total average of 9.27 (Table – 
9), the mutational status score was calculated as 9.27 - (1.96 x 1.83) = 5.68.   
Therefore, the mutational status can be determined as followed:                             
  ΔCt < 5.68 = Positive, and ΔCt ≥ 5.68 = Negative. 
From the given data, the average ΔCt value for Positive CAP samples was 
calculated as 0.29 for S2, and 2.93 for S3 with IC Ct values ranged from 27.30 –  
27.84.  The ΔCt values total average for Negative CAP samples S1 and S4 were 
8.40 and 12.98 respectively.  All results met the acceptance criteria set for this 
experiment (Table – 10).
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Table 10:  Accuracy Study Results - CAP samples S1, S2, S3, S4, Clamping Control, and Positive Control were all run in 
duplicates for Accuracy test.  The ΔCt values (FAM – HEX) for Positive CAP samples (S2, S3) were < 5.68; for Negative 
CAP samples (S1, S4) were > 5.68; and Hex channel shows IC Ct values = 25 < Ct < 31, all of which met the acceptance 
criteria set for this experiment. 
 
Discussion and Conclusion 
 
From this experiment, we can see that the “Proof of Concept” (PoC) study 
confirmed the feasibility of a 2-Step qPCR program for the ABI-QS5 cycler.  The 
newly established protocol tested and validated successfully on the ABI-QS5 
instrument.  Accuracy and Sensitivity of the assay were not affected by the 
changes of the thermocycling parameters.  For the LC 480, however, 
optimization of the 2-Step qPCR protocol did not work even with several 
modifications of the program including modification in the ramp rates and the 
annealing/extension time/temperatures.   
In conclusion, the new and improved thermocycling parameters can be used as a 
starting point for further feasibility work for the BRAF Codon 600 Specific 
Mutation Detection Assay on the ABI-QS5.  Although, clinical evaluation with 
more clinical samples is still needed to develop a more definitive mutational 
status acceptance criteria for the ABI-QS5.  Nevertheless, based on the obtained 
 
Sample 
ID 
 
FAM Channel Ct Values 
 
HEX Channel Ct Values 
ΔCt 
(FAM – 
HEX)  Replicate 1 Replicate 2 Average Replicate 1 Replicate 2 Average 
S1 36.78 38.29 37.54 28.35 29.93 29.14 8.40 
S2 28.42 27.44 27.93 27.84 27.44 27.64 0.29 
S3 30.32 30.58 30.45 27.73 27.30 27.52 2.93 
S4 41.01 40.87 40.94 27.80 28.11 27.96 12.98 
CC 38.44 38.25 38.35 27.44 27.52 27.48 10.87 
PC 30.08 30.28 30.18 26.99 27.07 27.03 3.15 
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results and due to the different platforms and technology between the tested 
instruments, further research and future experiments are needed to conclude the 
comparison and optimization of the 2-step real-time PCR protocol on the LC 480.  
Additionally, a better understanding of the effects of factors such as temperature, 
ramp rates, PCR enzymes/master mix, primer/probes and XNA concentrations 
can be further studied and tested out more extensively in future research for the 
optimization of the 2-step qPCR protocol in general, and for the optimization of 
the Light-Cycler platforms specifically, since cycling protocol that works on one 
brand of instrument may not necessarily work on another.
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